We are live on ! Find out more
ODTX icon

Odyssey Therapeutics

73 hedge funds and large institutions have $838M invested in Odyssey Therapeutics in 2026 Q3 according to their latest regulatory filings, with 22 funds opening new positions, 21 increasing their positions, 13 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

175% more first-time investments, than exits

New positions opened: 22 | Existing positions closed: 8

139% more capital inflows, than outflows

Capital inflows: $115M | Capital outflows: $48.1M

62% more repeat investments, than reductions

Existing positions increased: 21 | Existing positions reduced: 13

50% more funds holding in top 10

Funds holding in top 10: 6 → 9 (+3)

24% more funds holding

Funds holding: 59 → 73 (+14)

6.14% more ownership

Funds ownership: 72.65% → 78.78% (+6.1%)

Holders
73
Holders Change
+14
Holders Change %
+23.73%
% of All Funds
0.89%
Holding in Top 10
9
Holding in Top 10 Change
+3
Holding in Top 10 Change %
+50%
% of All Funds
0.11%
New
22
Increased
21
Reduced
13
Closed
8
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

ODTX Hedge Fund Activity: Q3 2026 in Review

73 of the 8,207 institutional investors tracked by Wall St. Rank reported a position in Odyssey Therapeutics (ODTX) for Q3 2026, worth a combined $838M — up 28% from $653M a quarter earlier.

Buyers outnumbered sellers: 22 funds opened new ODTX positions and 8 closed out — a net gain of 14 holders — while 21 added to existing stakes and 13 trimmed.

The largest buyer was MPM BioImpact, opening a new position worth an estimated $27.4M. The largest seller was Logos Global Management, exiting entirely with an estimated $9.8M sold.

  • 73 institutional investors held Odyssey Therapeutics (ODTX) as of Q3 2026, up from 59 in Q2 2026.
  • Funds reported $838M of Odyssey Therapeutics stock for Q3 2026, up 28% quarter-over-quarter.
  • 22 funds opened new Odyssey Therapeutics positions in Q3 2026 and 8 closed out, a net change of +14 holders.
  • The largest Odyssey Therapeutics buyer in Q3 2026 was MPM BioImpact, an estimated $27.4M added.
  • The largest Odyssey Therapeutics seller in Q3 2026 was Logos Global Management, an estimated $9.8M sold.

Based on aggregated 13F filings for Q3 2026.